Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System
Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb
Cost Savings with Biosimilars in Rheumatology: A Systematic Literature Search of Budget Impact Analysis
Implementation Strategies of Biosimilars in Healthcare Systems: The Path Forward
Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
OBSIDIAN – real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis
Biosimilars (National Psoriasis Foundation)
Position Statement on the Use of Biosimilars for Psoriasis and Psoriatic Arthritis
Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
